Kestrel Therapeutics, Inc.
1 clinical trials · Sponsor
◉ Watch Kestrel Therapeutics, Inc.
| Record | Firm | Date |
|---|---|---|
| A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation (NCT07458347) | Kestrel Therapeutics, Inc. | 2026-04-21 |
Track Kestrel Therapeutics, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.